Genomic Nanosystems Announced Today That It Has Received the Exclusive Patent Rights for Clonal Amplification and Digital PCR (Polymerase Chain Reaction) from Cytonix
Summary
Following amplification, a count of chambers containing detectable levels of PCR end product is a direct measure of the absolute nucleic acid quantity in the original sample.Conducting DigitalPCR in emulsions (dePCR) allows many millions of PCR reactions to occur in parallel, providing high precision and the ability to resolve rare events.Genomic Nanosystems is developing DigitalPCR products for a wide spectrum of applications, including detection of pathogens, cancer, fetal abnormalities and forensic evidence.Genomic Nanosystems plans to release a DigitalPCR kit this summer for dispersing PCR ready samples into millions of stable micelles in a hydrophobic matrix.Following amplification, a count of chambers containing detectable levels of PCR end product is a direct measure of the absolute nucleic acid quantity in the original sample.